First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Karim Fizazi, Arun A. Azad, Nobuaki Matsubara, Joan Carles, Andre P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C. C. Fong, Eric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G. Healy, Nicola Di Santo, A. Douglas Laird, Fabian Zohren, Neeraj Agarwal

Open source

DOI: 10.1038/s41591-023-02704-x
Published: 2023-12-04
Container: Nature Medicine
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-023-02704-x,
  title = {First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial},
  author = {Karim Fizazi and Arun A. Azad and Nobuaki Matsubara and Joan Carles and Andre P. Fay and Ugo De Giorgi and Jae Young Joung and Peter C. C. Fong and Eric Voog and Robert J. Jones and Neal D. Shore and Curtis Dunshee and Stefanie Zschäbitz and Jan Oldenburg and Dingwei Ye and Xun Lin and Cynthia G. Healy and Nicola Di Santo and A. Douglas Laird and Fabian Zohren and Neeraj Agarwal},
  year = {2023},
  journal = {Nature Medicine},
  doi = {10.1038/s41591-023-02704-x},
  url = {https://doi.org/10.1038/s41591-023-02704-x}
}

RIS

TY  - JOUR
TI  - First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
AU  - Karim Fizazi
AU  - Arun A. Azad
AU  - Nobuaki Matsubara
AU  - Joan Carles
AU  - Andre P. Fay
AU  - Ugo De Giorgi
AU  - Jae Young Joung
AU  - Peter C. C. Fong
AU  - Eric Voog
AU  - Robert J. Jones
AU  - Neal D. Shore
AU  - Curtis Dunshee
AU  - Stefanie Zschäbitz
AU  - Jan Oldenburg
AU  - Dingwei Ye
AU  - Xun Lin
AU  - Cynthia G. Healy
AU  - Nicola Di Santo
AU  - A. Douglas Laird
AU  - Fabian Zohren
AU  - Neeraj Agarwal
PY  - 2023
JO  - Nature Medicine
DO  - 10.1038/s41591-023-02704-x
UR  - https://doi.org/10.1038/s41591-023-02704-x
ER  -

APA

Fizazi, K., Azad, A. A., Matsubara, N., Carles, J., Fay, A. P., Giorgi, U. D., Joung, J. Y., Fong, P. C. C., Voog, E., Jones, R. J., Shore, N. D., Dunshee, C., Zschäbitz, S., Oldenburg, J., Ye, D., Lin, X., Healy, C. G., Santo, N. D., Laird, A. D., Zohren, F., & Agarwal, N. (2023). First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02704-x

Source records

crossref · retrieved 2026-09-26T23:57:12.755Z